|
|
Volumn 323, Issue 7316, 2001, Pages 767-
|
|
FDA warns Merck over its promotion of rofecoxib.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
LACTONE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
SULFONE;
WARFARIN;
ARTICLE;
CEREBROVASCULAR ACCIDENT;
CHEMICALLY INDUCED DISORDER;
DRUG CONTROL;
DRUG INDUSTRY;
DRUG INTERACTION;
FOOD AND DRUG ADMINISTRATION;
UNITED STATES;
ANTICOAGULANTS;
CEREBROVASCULAR ACCIDENT;
CYCLOOXYGENASE INHIBITORS;
DRUG AND NARCOTIC CONTROL;
DRUG INDUSTRY;
DRUG INTERACTIONS;
LACTONES;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
WARFARIN;
|
|
EID: 0035818381
PISSN: 09598138
EISSN: None
Source Type: Journal
DOI: 10.1136/bmj.323.7316.767a Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
